RobynYoungMD
Oncology • Fort Worth, TXBreast Cancer, Hematologic Oncology
Director of Breast Cancer at The Center for Cancer and Blood Disorders
Dr. Young is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
800 W Magnolia Ave
Fort Worth, TX 76104Phone+1 817-759-7000- Is this information wrong?
Education & Training
SUNY Upstate Medical UniversityFellowship, Hematology and Medical Oncology, 1993 - 1995- SUNY Upstate Medical UniversityResidency, Internal Medicine, 1990 - 1993
McGovern Medical School at UTHealthClass of 1990
Certifications & Licensure
TX State Medical License 1991 - 2025- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2014
Clinical Trials
- A Phase II Study of Everolimus in Combination With Exemestane Versus Everolimus Alone Versus Capecitabine in Advance Breast Cancer. Start of enrollment: 2013 Feb 26
- Study of Efficacy and Safety of LEE011 in Postmenopausal Women With Advanced Breast Cancer.(MONALEESA-2) Start of enrollment: 2013 Dec 17
- Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Start of enrollment: 2013 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 66 citationsLong-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow...C E Geyer, W M Sikov, J Huober, H S Rugo, N Wolmark, J O'Shaughnessy, D Maag, M Untch, M Golshan, J Ponce Lorenzo, O Metzger, M Dunbar, W F Symmans, P Rastogi, J H Soh...> ;Annals of Oncology. 2022 Apr 1
- 5 citationsA Phase II Study Evaluating Orteronel, an Inhibitor of Androgen Biosynthesis, in Patients With Androgen Receptor (AR)-Expressing Metastatic Breast Cancer (MBC).Denise A. Yardley, Robyn R. Young, Kerin B. Adelson, Andrea Silber, Jose E. Najera, Davey B. Daniel, N. W. Peacock, L Finney, Susan J. Hoekstra, Mythili Shastry, John ...> ;Clinical Breast Cancer. 2021 Oct 28
- 16 citationsThe efficacy and safety of enzalutamide with trastuzumab in patients with HER2+ and androgen receptor-positive metastatic or locally advanced breast cancerAndrew M Wardley, Javier Cortes, Louise Provencher, Kathy D. Miller, A. Jo Chien, Hope S. Rugo, Joyce Steinberg, Jennifer Sugg, Iulia Cristina Tudor, M.T. Huizing, Rob...> ;Breast Cancer Research and Treatment. 2021 Feb 16
- Join now to see all
Hospital Affiliations
Baylor Scott & White All Saints Medical Center - Fort WorthFort Worth, Texas
Texas Health Harris Methodist Hospital Fort WorthFort Worth, Texas
Texas Health Huguley Hospital Fort Worth SouthBurleson, Texas
Medical City Fort WorthFort Worth, Texas- Baylor Scott & White Institute for Rehabilitation-Fort WorthFort Worth, Texas
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
